Bill Nichols is Senior Vice President, Commercial at bluebird bio (blue), who has been setting the standard for gene therapy for more than a decade—first as a scientific pioneer and now as a commercial leader.
In this role, Nichols serves as a cross functional leader responsible for strategic planning and operations across all three of bluebird bio’s GT assets in rare disease—Sickle Cell Disease, Transfusion Dependent Thalassemia and Cerebral Adrenoleukodystrophy.
During his 20+ year career in Biotech and BioPharma, Bill has deep experience across multiple pre-launch and commercial roles focused on addressing the needs of rare and underserved communities.
Prior to his tenure at blue, Bill worked at Bristol-Myers Squibb and Dova Pharmaceuticals, now Sobi, where he launched or led numerous brands in disease states ranging from Major Depressive Disorder (MDD), HIV, Hepatitis B and Hepatitis C, and Oncology.
In addition to his professional career, Bill is a member of Kappa Alpha Psi Fraternity, Inc. and an advisor to Young Black Pharma and Brothers of Color in Pharma (BROCIP).
Nichols holds a Bachelor of Science degree in Biology from Morehouse College and multiple advanced degree certificates from Wharton.
